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MicroRNAs (miRNAs) have been reported to play signiﬁcant roles in the pathogenesis of various pol-
yQ diseases. This study aims to investigate the regulation of ATXN3 gene expression by miRNA. We
found that miR-25 reduced both wild-type and polyQ-expanded mutant ataxin-3 protein levels by
interacting with the 30UTR of ATXN3 mRNA. miR-25 also increased cell viability, decreased early
apoptosis, and downregulated the accumulation of mutant ataxin-3 protein aggregates in SCA3/
MJD cells. These novel results shed light on the potential role of miR-25 in the pathogenesis of
SCA3/MJD, and provide a possible therapeutic intervention for this disorder.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Spinocerebellar ataxia type 3/Machado–Joseph disease (SCA3/
MJD), the most common type of inherited spinocerebellar ataxia
worldwide, is a polyglutamine (polyQ) disease; these neurodegen-
erative illnesses are caused by glutamine-encoding CAG nucleotide
expansions within endogenous human genes. In healthy individu-
als, the wild-type ataxin-3 protein (encoded by the wild-type
ATXN3 gene) has between 12 and 40 CAG repeats, and results in
no cellular toxicity. However, in SCA3/MJD, the polyQ-expanded
ATXN3 gene encodes between 51 and 86 CAG repeats (http://neu-
romuscular.wustl.edu/index.html), resulting in an abnormal polyQ
tract in the polyQ-expanded mutant ataxin-3 protein [1–6]. This
protein, in turn, accumulates microscopically discernible aggrega-
tions—called neuronal intranuclear inclusions (NII)—in the nucleus
and adjacent areas of the affected neurons, and can exacerbate celldeath [2,7–9]. Downregulation of toxic ataxin-3 protein levels pre-
vents the progression of SCA3/MJD [10–12].
MicroRNAs (miRNAs) are a group of endogenous non-coding
RNAs that play a critical role in metabolism, neurodevelopment,
neuroplasticity, apoptosis, and other fundamental neurobiological
processes and diseases [13,14]. Recent studies have suggested that
miRNAs are a signiﬁcant player in mediating the pathogenesis of
various polyQ diseases, including spinocerebellar ataxia, SBMA
and Huntington’s disease [15–19]. For instance, in a human cell
model of SCA1, miR-19, miR-101, and miR-130 were shown to
directly target ATXN1 mRNA expression; in contrast, mutation of
the target sites of miR-101 and miR-130 within the 30UTR exacer-
bated ATXN1 cytotoxicity [20]. Moreover, miR-150 levels in SCA1
Purkinje neurons were found to modulate disease pathogenesis
by targeting the 30UTR of Rgs8 and Vegfa [21]. Another study found
that miR-29a and miR-29b were downregulated in a cellular model
of SCA17, and that miR-29a/b expression was inversely correlated
with BACE1 expression [22]. In SCA3/MJD, the miRNA bantam was
found to be a potent modulator of ataxin-3 cytotoxicity in Drosoph-
ila, and eliminating miRNAs via mutation in Dicer led to enhanced
polyQ-mediated toxicity [23]. In a SCA3/MJD mouse model, anti-
ATXN3 miRNA mimics effectively suppressed human ATXN3
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mutant ataxin-3 throughout the cerebellum [24].
A previous study from our laboratory reported four dysregu-
lated miRNAs in SCA3/MJD patients: miR-25, miR-125b, miR-29a,
and miR-34b [25]. Building on this work, we hypothesized that
miRNA-mediated regulation of ATXN3 might also modulate SCA3/
MJD neuropathology via previously unknown mechanisms. The
present study investigated the role of miRNAs in the regulation
of SCA3/MJD.2. Materials and methods
2.1. Plasmid and siATXN3 construction
For SCA3/MJD model cells, the ATXN3 cDNA in the plasmid,
which was a truncated fragment of 68 CAG repeats, was inserted
into the pEGFP-C1 vector (Clontech, Palo Alto, CA, USA) and the
pcDNA3.1/myc-His()B vector (Invitrogen, Carlsbad, CA, USA),
respectively. For the pmirGLO-ATXN3 30UTR-WT vector (referred
to as ATXN3 30UTR-WT), the 1531 bp region of the human ATXN3
gene (NM_004993.5) containing the miR-25 binding site (259–
266) was cloned into the pmirGLO Dual-Luciferase miRNA Target
Expression Vector (Promega, Madison, WI, USA). For the pmir-
GLO-ATXN3 30UTR-MUT vector (referred to as ATXN3 30UTR-MUT),
the GTGCAATA sequence was mutated to CTCGATAA. For positive
control in luciferase assay, the perfect miR-25 binding sites (The
sequence was TCAGACCGAGACAAGTGCAATG) were inserted into
the pmirGLO Dual-Luciferase miRNA Target Expression Vector
(referred to as positive control). The followingwere used as positive
controls for siATXN3 sequences: siATXN3-WT: AGCAGCAGGGG-
GACCTATC and siATXN3-MUT: AGCAGCAGCGGGACCTATC.
2.2. Cell cultures
HEK 293T cells (National Key Laboratory of Medical Genetics,
Changsha, China) were routinely cultured in high glucose DMEM
supplemented with 10% heat-inactivated fetal bovine serum,
100 U/ml penicillin, and 100 U/ml streptomycin (Gibco, Carlsbad,
CA, USA) at 37 C in a 5% CO2 incubator. By using lipofectamine
2000 (Invitrogen), HEK 293T cells transfected with pcDNA3.1/myc-
His()B-ATXN3-68Q, pcDNA3.1/myc-His()B-ATXN3-68Q-30UTR-
WT, pEGFP-C1-ATXN3-68Q, or pEGFP-C1-ATXN3-68Q-30UTR-WT
(referred to as pcSCA3/MJDtr-68Q, pcSCA3/MJDtr-68Q-UTR,
pSCA3/MJDtr-68Q or pSCA3/MJDtr-68Q-UTR, respectively), were
used to establish SCA3/MJD model cells, and also routinely cultured
using the same methods as for HEK 293T cells (Supplement mate-
rial). SH-SY5Y human neuroblastoma cells (SH-SY5Y cells) were cul-
tured inDMEM/F-12mediumsupplementedwith10%FBS, 100 U/ml
penicillin, 100 U/ml streptomycin, 1% MEM non-essential amino
acids, and 4 mM L-glutamine (Gibco) at 37 C in a 5% CO2 incubator.
2.3. Quantitative real-time polymerase chain reaction (RT-qPCR) for
mRNA
HEK 293T cells, SH-SY5Y cells, and SCA3/MJD model cells
(pSCA3/MJDtr-68Q-UTR) were plated in six-well plates and trans-
fected with miRNA mimics or siATXN3 (The ﬁnal concentration
of miRNA mimics and siATXN3 was 50 nmol/L in the whole exper-
iment). Forty-eight hours later, total RNA was extracted using Tri-
zol reagent (Invitrogen). Reverse transcription was carried out in a
20 ll reaction volume using RevertAid First Strand cDNA Synthesis
Kit (Fermentas, Glen Burnie, Maryland, USA). Quantitative PCR was
carried out in a 25 ll reaction volume containing SYBR Premix ExTaq™ (TaKaRa, Dalian, China) and 0.2 lM primers (ATXN3-F:
GGCTCACTTTGTGC TCAACATTG; ATXN3-R: TCTCATCCTCTCCTCCT-
CATCCAG) according to the manufacturer’s instructions. A Bio-
Rad thermal cycler was programmed for an initial denaturation
step (95 C, 30 s) followed by 40 ampliﬁcation cycles (95 C, 5 s;
60 C, 30 s). b-Actin was used as an internal reference. Differences
between control and experimental samples were calculated using
the 2DDCt method.
2.4. Western blotting
The same cell types and transfection steps were used as in the
RT-qPCR method described above. Forty-eight hours later, cells
were harvested and lysed with 100 ll radio-immunoprecipitation
assay (RIPA) buffer containing 1  protease inhibitor cocktail on
ice for 15 min. The cell lysate was centrifuged at 13000xg for
20 min, and the supernatant was mixed with an equal volume of
sample buffer. Proteins were separated by 10% sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis (SDS–PAGE) and trans-
ferred to a polyvinylidene diﬂuoride membrane (Millipore,
Billerica, MA, USA). After blocking with 5% non-fat milk at room
temperature for one hour, the membrane was washed three times
with Tris-Buffered Saline and Tween 20 (TBST), then incubated
with diluted primary antibodies overnight at 4 C, or for 2 h at
room temperature with anti-ATXN3 (Millipore) at 1:10000, anti-
GFP (Clontech, Mountain View, CA, USA) at 1:10000, or anti-b-
actin (Sigma, St. Louis, MO, USA) at 1:10000. After washing three
times with TBST, the membrane was incubated with diluted sec-
ondary antibody for one hour at room temperature with anti-
mouse antibody at 1:10000. Protein bands were visualized using
enhanced chemiluminescence (ECL) reagents (Thermo Fisher Sci-
entiﬁc, Rochford, IL, USA) as recommended after three washes.
The ﬁlm was analyzed using ImageJ software. The stable transfec-
tion of pcSCA3/MJDtr-68Q model cells was also veriﬁed by Wes-
tern Blot.
2.5. Dual luciferase assay
HEK 293T cells were co-transfected with miRNAs and pmirGLO-
ATXN3-30UTR-WT vector (or pmirGLO-ATXN3-30UTR MUT vector)
in a 24-well plate. Twenty-four hours after transfection, cells were
harvested and lysed in passive lysis buffer (PLB; Promega, Madison,
WI, USA) followed by the addition of 20 ll of Dual-Glo Reagent.
Ten minutes later, ﬁreﬂy luminescence was measured in a Glomax
luminometer (Turner Designs, Sunnyvale, CA, USA). A volume of
Dual-Glo Stop & Glo Reagent equal to the Dual-Glo Reagent
was added to each well, and Renilla luminescence was measured
10 min later. Fireﬂy luciferase activity was normalized by Renilla
luciferase activity, and this ratio was then normalized to that of a
control well transfected with miRNA negative mimics. Finally,
the relative response ratios were calculated from the normalized
ratios.
2.6. Cell viability analysis using 3-(4,5-dimethylthiazol-2-yl)-2,5-
dipheyltetrazolium bromide (MTT) assay and clonogenic assay
For the MTT assay [4], SCA3/MJD model cells established using
the HEK 293T cell line (pcSCA3/MJDtr-68Q or pcSCA3/MJDtr-68Q-
UTR) were cultured in 96-well plates and transfected with miRNA
mimics or siATXN3-MUT. Cells were harvested at 0, 24, and 48 h
after transfection. Each well received 100 ll of MTT solution (5 g/l;
Sigma) and the supernatant was carefully removed four hours
later. MTT crystals were dissolved in l00 ll dimethyl sulfoxide
(DMSO; Sigma), and optical density was measured at the optimal
Table 1
Four candidate miRNAs and related central nervous system (CNS) diseases.
miRNAs Related diseases
miR-29a Spinocerebellar ataxia 17 [22],
Alzheimer’s disease [26–28]
miR-125b Spinocerebellar ataxia 1 [21],
Alzheimer’s disease [29], Huntington’s disease [30]
miR-25 Schizophrenia [31], autism spectrum disorders [32]
miR-34b Huntington’s disease [19], Parkinson’s disease [33,34]
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(Thermo Fisher Scientiﬁc). The background absorbance of the med-
ium was subtracted.
Clonogenic assays were performed to determine the effect of
miR-25 on model SCA3/MJD cell growth. As MTT, we harvested
cells at 24 h after miRNA mimics or siATXN3-MUT transfection.
Then cells were seeded in 6-well plates with 500 cells/well. Each
well contained 1.5 mL DMEM medium containing 10% FBS. Colo-Fig. 1. Regulation of ATXN3 gene expression by miR-25. (A, C, and E) Using RT-qPCR an
mutant ATXN3mRNA expression in the miR-25 group. In contrast, siATXN3 acting as a pos
25 reduced levels of both wild-type and polyQ-expanded mutant ataxin-3 protein in thre
protein are shown (negative control = 1). Error bars represent S.E.M. ⁄P < 0.05 compared
negative control, miR-29a mimics, miR-34b mimics, miR-125b mimics, miR-25 mimics,nies were counted 15 days later. The colonies were stained with
Giemsa and quantiﬁed. Cloning efﬁciency = number of colonies/
number of seeded cells * 100%. Untreated control group was
assigned a value of 100% growth.
Each assay was performed in triplicate, and the mean for each
experiment was calculated.
2.7. Early cell apoptosis rate analysis by Flow cytometry (FCM)
For the FCM assay [5], SCA3/MJD model cells (pcSCA3/MJDtr-
68Q or pcSCA3/MJDtr-68Q-UTR) were plated in 6 cm tissue culture
dishes and transfected with miRNA mimics or siATXN3-MUT.
Forty-eight hours later, cells were harvested and apoptotic cells
were quantiﬁed by double staining with ﬂuorescein isothiocyanate
(FITC)-conjugated Annexin V and propidium iodide (PI) using
Annexin V/PI apoptosis kit (Invitrogen) to label dead or damaged
cells. Brieﬂy, cells were washed with PBS twice and stained with
Annexin V and PI for 15 min at room temperature in the dark.
The level of apoptosis was determined by measuring the ﬂuores-alysis, no difference was observed in levels of either wild-type or polyQ-expanded
itive control showed signiﬁcant reductions in ATXN3mRNA levels. (B, D, and F) miR-
e cell lines. Representative Western blot images and mean relative levels of ataxin-3
to negative control. In Fig. 1A, control, 29a, 34b, 125b, 25, and siATXN3-WT refer to
and siATXN3-WT mimics, respectively.
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Coulter FC500, Fullerton, CA, USA). Samples were immediately
measured for ﬂuorescence emission at an excitation wavelength
of 488 nm. The number of cells used by was approximately
20000. Four cellular subpopulations were evaluated: vital cells
(annexin V/PI), early apoptotic cells (annexin V+/PI), late
apoptotic cells (annexin V+/PI+), and necrotic/damaged cells
(annexin V/PI+). Annexin V+/PI cells were considered to be
early apoptotic cells.
2.8. Immunoﬂuorescence assays and laser scanning confocal detection
For immunoﬂuorescence, SCA3/MJD model cells (pSCA3/MJDtr-
68Q or pSCA3/MJDtr-68Q-UTR) were plated in 24-well plates and
transfected with miRNA mimics or siATXN3-MUT [4,5]. Forty-eight
hours after transfection, cells were counted in random ﬁelds from
three different quadrants of the culture well using an inverted
microscope (Olympus IX-71, Melville, NY, USA). Cells were counted
in ﬁelds selected at random from ﬁve different quadrants of the
culture well. Counting was performed by an investigator blind to
the experimental conditions. Also, the immunoﬂuorescence den-
sity of aggregates was measured by ImageJ software. For laser
scanning confocal detection, cells were ﬁxed with 4% paraformal-
dehyde at 37 C for 30 min and permeabilized with 0.1%
Triton-X100 in PBS at 37 C for 30 min. After incubation with 40-
6-diamidino-2-phenylindole (DAPI, 5 mg/ml) for 15 min, samples
were mounted in ﬂuoromount medium (Sigma) and examined
with a laser scanning confocal system installed on a confocal laser
microscope (Leica TCS SP5, Heidelberg, Germany). The images
were analyzed using the Metaphor software package.
2.9. Statistical analysis
Results were drawn from at least three independent experi-
ments. All data are expressed as mean ± S.E.M. Statistical analysesFig. 2. miR-25 directly targets the 30 UTR of ATXN3. (A) The bioinformatics algorithms
contains a miR-25 binding site at position 259–266 of the ATXN3 30UTR. (B) The ATXN3 30U
sequence was mutated to CTCGATAA) was fused to the 30 end of a luciferase gene. (C) Du
WT (with a partly miR-25 binding site), ATXN3 30UTR-MUT (with a mutated miR-25 bind
The results revealed that miR-25 mimics signiﬁcantly reduced the expression of ﬁreﬂy lu
30UTR-MUT. Error bars represent S.E.M. ⁄P < 0.05 compared to the negative mimic contrwere performed using SPSS 18.0 by one-way analysis of variance
(ANOVA). P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. miR-25 regulates ATXN3 expression
Using miRCURY™ LNA Array followed by RT-qPCR analysis, our
previous study found that four miRNAs were dysregulated in SCA3/
MJD patients (miR-25, miR-125b, miR-29a, and miR-34b). Among
the four miRNAs, miR-34b expression was signiﬁcantly elevated
(The fold change was 2.35), whereas the levels of miR-29a, miR-
25, and miR-125b were decreased (The fold change was 0.79,
0.69 and 0.56, respectively.) [25]. Because these four miRNAs
appear relevant to the pathophysiology of neurological, neurode-
generative, and neuropsychiatric diseases (Table 1), the present
study further explored the mechanisms underlying their involve-
ment in regulating SCA3/MJD pathogenesis.
To test the effects of miR-25, miR-29a, miR-125b, and miR-34b
on ATXN3 gene expression, we transfected each miRNA mimic into
HEK 293T cells, then measured wild-type endogenous ATXN3
mRNA and ataxin-3 protein. We used HEK 293T cells because our
previous studies have found that polyQ expanded ATXN3 contrib-
ute to SCA3 pathogenesis in this cell line [4,5], and more impor-
tantly, because molecular mechanisms that contribute to SCA3
pathogenesis in the cerebellum have been reproduced in this cell
line in terms of the toxic polyQ expanded ataxin-3 protein [35].
None of these miRNA mimics affected ATXN3 mRNA levels. How-
ever, miR-25 signiﬁcantly decreased wild-type endogenous
ataxin-3 protein levels; the other three miRNAs had no such effect
(Fig. 1A and B). As a result, all additional experiments were carried
out only on miR-25.
SH-SY5Ycellswereusedasamorephysiologically relevantmodel
because the ATXN3 gene is abundantly expressed in these neurons.
Moreover, because SCA3/MJD is caused by the polyQ-expanded, including miRBase, PicTar, TargetScan and miRanda, identiﬁed the ATXN3 mRNA
TR-WT (the 259–266 sequence was GTGCAATA) or ATXN3 30UTR-MUT (the 259–266
al luciferase activity assays of co-transfections were performed using ATXN3 30UTR-
ing site) or positive control (with a perfect miR-25 binding site) and miR-25 mimics.
ciferase when fused to the ATXN3 30UTR-WT or positive control, but not the ATXN3
ol.
Fig. 3. miR-25 increases cell viability in SCA3/MJD model cells. Statistical analysis
of cell viability as measured by MTT assay of SCA3/MJD model cells untreated or
treated with miR-25 mimics, siATXN3-MUT, and negative mimics at 0, 24, and 48 h.
(A) miR-25 mimics signiﬁcantly increased cell viability 48 h after transfection; no
difference was detected at 0 or 24 h after transfection. As a positive control,
siATXN3-MUT also signiﬁcantly increased cell viability of SCA3/MJD model cells
48 h after transfection. (B) Signiﬁcant increase in colony number was observed in
miR-25 and siATXN3-MUT group. (A and B) Statistically higher cell viability was
also observed in pSCA3tr-68Q-UTR+miR-25 versus pSCA3tr-68Q+miR-25. Error bars
represent S.E.M. ⁄P < 0.05 compared to the corresponding negative mimic control.
Group 1: pcSCA3/MJDtr-68Q-UTR; group 2: pcSCA3/MJDtr-68Q-UTR+negative
mimics; group 3: pcSCA3/MJDtr-68Q-UTR+siATXN3-MUT; group 4: pcSCA3/
MJDtr-68Q-UTR+miR-25 mimics; group 5: pcSCA3/MJDtr-68Q+miR-25 mimics.
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gating the effect of miR-25 on the wild-type ATXN3 gene in SH-
SY5Y cells and on the polyQ-expanded ATXN3 gene in SCA3/MJD
model cells is of particular interest. As expected, no change in ATXN3
mRNA was observed. Ataxin-3 protein levels were markedly
decreased in both SH-SY5Y (Fig. 1C andD) and SCA3/MJDmodel cells
(Fig. 1EandF),whichwasconsistentwith theeffects observed inHEK
293T cells.
3.2. miR-25 directly targets the 30 UTR of ATXN3
miRNAs normally target the 30UTR of mRNAs [36–39]. To under-
stand the possible mechanisms of SCA3/MJD that miR-25 partici-
pated, we searched for potential gene targets of miR-25 using the
bioinformatics algorithms, including miRBase, PicTar, TargetScan
and miRanda. All of the algorithms identiﬁed ATXN3 as a target
of miR-25, based on putative target sequences at position 259–
266 of the ATXN3 30 UTR (Fig. 2A). To verify the targets of miR-25
on the 30 UTR of ATXN3, an ATXN3 30UTR-WT (the 259–266
sequence was GTGCAAT) or an ATXN3 30UTR-MUT (the 259–266
sequence was mutated to CTCGATA) was fused to the 30 end of a
luciferase gene (Fig. 2B). As shown in Fig. 2C, co-transfection ofmiR-25 mimics signiﬁcantly suppressed the luciferase activity elic-
ited by the luciferase-ATXN3 30UTR-WT construct, which was sim-
ilar to the positive control, but had no effect on the luciferase
activity elicited by an ATXN3 30UTR-MUT construct(Fig. 2C). These
results suggest that miR-25 might regulate ATXN3 expression by
targeting the speciﬁc 30UTR of ATXN3 mRNA.
3.3. miR-25 increases cell viability in SCA3/MJD model cells
To examine whether miR-25 affects the cytotoxicity induced by
polyQ-expanded mutant ataxin-3 protein, we transfected miR-25
mimics into SCA3/MJD model cells (pcSCA3/MJDtr-68Q-UTR), and
measured cell viability via MTT and clonogenic assay. As shown
in Fig. 3A, miR-25 signiﬁcantly increased cell viability 48 h after
transfection compared with the corresponding negative control;
no signiﬁcant effects were observed at 0 or 24 h. siATXN3-MUT
transfection also signiﬁcantly increased pcSCA3/MJDtr-68Q-UTR
cell viability at 48 h. Further, miR-25 signiﬁcantly increased colony
formation of model SCA3/MJD cells compared with negative con-
trol group (Fig. 3B). Interestingly, a statistically signiﬁcant increase
in cell viability was observed between pcSCA3/MJDtr-68Q-UTR+
miR-25 and pcSCA3/MJDtr-68Q+miR-25, further conﬁrming that
the neuroprotective effects of miR-25 were caused by interactions
between miR-25 and 30UTR.
3.4. miR-25 suppresses apoptosis in SCA3/MJD model cells
Although the molecular pathogenesis of SCA3/MJD remains
unknown, considerable evidence suggests that apoptosis is at least
partly involved in the neurodegenerative aspects of this disorder
[40–42]. The stable transfection of pcSCA3/MJDtr-68Q model cells
was veriﬁed byWestern blot method (Fig. 4A). To assess the effects
of miR-25 on apoptosis in SCA3/MJD model cells, ﬂow cytometry
assays were conducted at 24 h and 48 h after transfection with
or without miR-25 mimics (Fig. 4B). As shown in Fig. 4C, transfec-
tion of miR-25 mimics signiﬁcantly lowered early apoptotic rates
in SCA3/MJD model cells at 48 h, but without 24 h. However,
miR-25 failed to alter the early apoptotic rate in the stably trans-
fected cells expressing the pcSCA3/MJDtr-68Q lacking the 30UTR
of ATXN3, again suggesting a speciﬁc role for 30UTR of ATXN3 in
mediating miR-25 function, Furthermore, late apoptotic rates both
at 24 h and 48 h had no changes (Fig. 4D).
3.5. miR-25 suppresses polyQ-expanded ataxin-3 protein aggregate
formation
PolyQ-expanded mutant ataxin-3 protein has been found to be
misfolded and aggregated in the nucleus and nearby loci, leading to
accelerated cell death [4,7,8]. In order to expand our molecular
analysis, GFP-tagged SCA3/MJD model cells (pSCA3/MJDtr-68Q or
pSCA3/MJDtr-68Q-UTR) were used to detect mutant ataxin-3 pro-
tein aggregation. And we quantiﬁed aggregate formation cells and
immunoﬂuorescence density of aggregates by ﬂuorescence imag-
ing and imageJ computational analysis [4]. As predicted, miR-25
reduced the amount of mutant ataxin-3 protein aggregations in
mutant ataxin-3-expressing cells (Fig. 5A). However, the immuno-
ﬂuorescence density of aggregates had no signiﬁcant difference
with or without miR-25 mimics (Fig. 5B). To locate the ataxin-3
protein aggregates, nuclei were stained by DAPI, and ﬂuorescent
microscopy was performed. Results showed the expression of
ataxin-3-68Q-GFP protein (green) and DAPI stained nuclei (blue)
in the same SCA3/MJD model cells. Diffused distribution of the
mutant ataxin-3 protein was detected in the area adjacent to the
nucleus (Fig. 5C).
Fig. 4. miR-25 suppresses apoptosis in SCA3/MJD model cells. (A) The stable transfection of pcSCA3/MJDtr-68Q model cells was veriﬁed by Western blot method (Fig. 4A).
Group 1: pcDNA3.1/myc-His()B; group 2: pcSCA3/MJDtr-68Q-UTR; group 3: pcSCA3/MJDtr-68Q. (B) The upper right quadrant [Annexin V (+)/PI (+)] contained the late
apoptotic and necrotic population, and the lower right quadrant [Annexin V (+)/PI ()] contained the early apoptotic population in the ﬂow cytometry assay. (C and D)
Apoptosis was analyzed by ﬂow cytometry analysis after staining with Annexin V and PI. miR-25 mimics signiﬁcantly reduced the early apoptotic rate in SCA3/MJD model
cells after 48 h, without affecting early apoptotic rate at 24 h and late apoptotic rate both at 24 h and 48 h. Data represent mean ± S.E.M. ⁄P < 0.05 compared to the
corresponding negative control. Group 1: pcSCA3/MJDtr-68Q-UTR; group 2: pcSCA3/MJDtr-68Q-UTR+negative mimics; group 3: pcSCA3/MJDtr-68Q-UTR+siATXN3-MUT;
group 4: pcSCA3/MJDtr-68Q-UTR+miR-25 mimics; group 5: pcSCA3/MJDtr-68Q+miR-25 mimics.
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The current study investigated the role of miRNAs in the regu-
lation of SCA3/MJD. We provide the ﬁrst evidence that miR-25
overexpression led to reduced levels of endogenous wild-type
ataxin-3 protein without affecting ATXN3 mRNA expression. The
three other miRNAs investigated—miR-29a, miR-125b, miR-34b—
all failed to affect endogenous wild-type ATXN3 expression. To fur-
ther validate miR-25 function, we also transfected miR-25 mimics
into SH-SY5Y cells, with similar results to those obtained in HEK
293T cells. These data suggest that miRNAs participate in thepost-transcriptional regulation of gene expression, while siRNAs
modulate gene expression through mRNA degradation. In SCA3/
MJD model cells, miR-25 decreased exogenous polyQ-expanded
ataxin-3 protein expression without altering ATXN3 mRNA levels.
Together, the data show that miR-25 levels correlated at least par-
tially with ATXN3 gene expression.
No previous study has implicated miR-25 in polyQ diseases. Our
results provide the ﬁrst evidence that ATXN3 mRNA is a target for
miR-25, which is consistent with the main regulatory mechanisms
of miRNAs in other diseases such as SCA1 and Huntington’s Disease
[20,43]. Using MTT and FCM assays in SCA3/MJD model cells, we
Fig. 5. miR-25 suppresses aggregate formation of polyQ-expanded ataxin-3 protein. (A) Positive cell rate indicates the percentage of cells with NII in total cells. A statistically
signiﬁcant reduction in the amount of mutant ataxin-3 protein aggregates in siATXN3-MUT and miR-25 groups was observed. (B) miR-25 mimics did not affect the
immunoﬂuorescence density of aggregates. Error bars represent S.E.M. ⁄P < 0.05. Group 1: pSCA3/MJDtr-68Q-UTR; group 2: pSCA3/MJDtr-68Q-UTR+negative mimics; group
3: pSCA3/MJDtr-68Q-UTR+siATXN3-MUT; group 4: pSCA3/MJDtr-68Q-UTR+miR-25 mimics; group 5: pSCA3/MJDtr-68Q+miR-25 mimics. (C) Laser scanning confocal
detection showing the expression of ataxin-3-68Q-GFP protein (green) and DAPI stained nucleus (blue) in the same SCA3/MJD model cell. Signiﬁcant diffuse staining of
mutant ataxin-3 protein was observed in the perinuclear region.
F. Huang et al. / FEBS Letters 588 (2014) 4791–4798 4797also found that miR-25 substantially affected polyQ-mediated
cytotoxicity, resulting in increased cell viability and decreased
early apoptosis. miR-25 was found to reduce NII formation, which
is mainly concentrated in the area adjacent to the nucleus (Fig. 5).
These results echoed the effects of treatment with the mood stabi-
lizers valproate and lithium in a Drosophila model of SCA3/MJD
[5,12]. Taken together, the results implicate miR-25 as a possible
therapeutic target candidate for SCA3/MJD, and suggest that miR-
NA-mediated regulation of RNA metabolism has a potential role
in treating SCA3/MJD and other polyQ diseases.
In summary, our study found that miR-25 reduced both endog-
enous wild-type and exogenous polyQ-expanded ataxin-3 protein
expression levels in different cell types without affecting ATXN3
mRNA expression. We conﬁrmed that miR-25 could directly target
the 30UTR of the ATXN3 gene and, further, found that miR-25 over-
expression reduced polyQ-induced toxicity and NII formation in
SCA3/MJD model cells. This identiﬁcation of a commonmechanism
of miRNA-mediated neuroprotection or neurodegeneration not
only enhances our understanding of the pathophysiology of
SCA3/MJD, but also provides a promising prospect for its treat-
ment. These novel results shed new light on the role of miR-25
in the pathogenesis of SCA3/MJD and suggest a possible new ther-
apeutic strategy for treating this and other polyQ diseases.
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